Glycated albumin refers to albumin that is nonenzymatically bound to glucose. It represents the average blood glucose level over the past 2–3 weeks and is an indicator of long-term glycemic control in patients with diabetes. The test is useful for monitoring glucose levels in patients with conditions affecting hemoglobin such as chronic kidney disease or hemoglobinopathies where HbA1c may not accurately reflect glycemic control. The global Glycated Albumin Assay Market is estimated to be valued at US$ 150 million in 2023 and is expected to exhibit a CAGR of 20% over the forecast period 2024-2031, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The rising prevalence of diabetes across the globe has been a key driver bolstering demand for glycated albumin assays. According to the International Diabetes Federation, approximately 537 million adults were living with diabetes in 2021 worldwide and the number is estimated to rise to 643 million by 2030 and 784 million by 2045. Glycated albumin level measurement provides clinicians with additional information regarding a patient's short-term glycemic control that is not captured by HbA1c testing alone. As more diabetologists recognize the clinical utility of glycated albumin assays especially in high-risk patient groups, testing volumes are expected to increase substantially over the forecast period.

Segment Analysis
The global Glycated Albumin Assay market is dominated by pathology labs and hospitals segment. The increasing number of diagnostic tests carried out in hospitals and pathology labs for monitoring diabetes and controlling its progression has been a major driver for this segment's dominance. Pathology labs and hospitals cumulatively account for over 60% market share owing to large volume of tests carried out on regular basis in these settings for diabetes management and care.

Key Takeaways
The Global Glycated Albumin Assay Market Demand is expected to witness high growth over the forecast period of 2024 to 2031.

Regional analysis: North America region currently dominates the global market due to presence of major players and developed healthcare infrastructure which promotes early diagnosis and management of conditions like diabetes. However, Asia Pacific region is expected to grow at fastest pace during the forecast period owing to rising diabetes prevalence, growing medical tourism and rapidly evolving healthcare scenario in various countries like India and China.

Key players operating in the Glycated Albumin Assay market are Asahi Kasei Pharma, DIAZYME, LifeSpan, Exocell, BSBE, Medicalsystem, Maccura, Leadman, Simes Sikma, NINGBO PUREBIO. Asahi Kasei Pharma currently dominates the market owing to its robust glyacated albumin assay product portfolio and global sales and distribution network. DIAZYME is another major player known for its glycated albumin selective kits and reagents.

For more details on the report, Read- https://www.insightprobing.com/global-glycated-albumin-assay-market-size-and-share/

Get more insights on this topic: https://lotstoexpress.com/gummy-bliss-tasty-health-booster-for-a-vibrant-you-chewable-wellness-wonder/